JP2004514423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004514423A5 JP2004514423A5 JP2002525238A JP2002525238A JP2004514423A5 JP 2004514423 A5 JP2004514423 A5 JP 2004514423A5 JP 2002525238 A JP2002525238 A JP 2002525238A JP 2002525238 A JP2002525238 A JP 2002525238A JP 2004514423 A5 JP2004514423 A5 JP 2004514423A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding portion
- isolated
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 146
- 102000036639 antigens Human genes 0.000 claims description 142
- 108091007433 antigens Proteins 0.000 claims description 142
- 210000004027 cell Anatomy 0.000 claims description 64
- 150000007523 nucleic acids Chemical group 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 17
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 230000009261 transgenic effect Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 102000000989 Complement System Proteins Human genes 0.000 claims description 9
- 108010069112 Complement System Proteins Proteins 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 101150109698 A2 gene Proteins 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 102000034285 signal transducing proteins Human genes 0.000 claims description 2
- 108091006024 signal transducing proteins Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 6
- 210000004602 germ cell Anatomy 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 6
- 239000003053 toxin Substances 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- 241000283690 Bos taurus Species 0.000 claims 3
- 241000699800 Cricetinae Species 0.000 claims 3
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 3
- 229940027941 immunoglobulin g Drugs 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 241000283707 Capra Species 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 210000003501 vero cell Anatomy 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 101150064109 4b gene Proteins 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 239000007801 affinity label Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 241001255830 Thema Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23064000P | 2000-09-07 | 2000-09-07 | |
| US25947201P | 2001-01-03 | 2001-01-03 | |
| PCT/US2001/028019 WO2002020619A2 (en) | 2000-09-07 | 2001-09-07 | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004514423A JP2004514423A (ja) | 2004-05-20 |
| JP2004514423A5 true JP2004514423A5 (cg-RX-API-DMAC7.html) | 2008-10-23 |
Family
ID=26924418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002525238A Pending JP2004514423A (ja) | 2000-09-07 | 2001-09-07 | トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7972845B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1319025A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004514423A (cg-RX-API-DMAC7.html) |
| AU (1) | AU8886601A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2422204A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002020619A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1319025A2 (en) | 2000-09-07 | 2003-06-18 | John R. Schreiber | Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| ATE458006T1 (de) * | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| EP1706425A2 (en) | 2003-12-05 | 2006-10-04 | John R. Schreiber | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse® |
| WO2006025995A2 (en) * | 2004-07-27 | 2006-03-09 | The Regents Of The University Of California | Compositions and methods using md-2 mutants and chimeric proteins |
| AU2005313971B2 (en) * | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| EP1690875A1 (en) * | 2005-02-14 | 2006-08-16 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| WO2017083515A2 (en) * | 2015-11-10 | 2017-05-18 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
| JP7303110B2 (ja) * | 2017-01-18 | 2023-07-04 | ビステラ， インコーポレイテッド | 抗体分子－薬物コンジュゲートおよびその使用 |
| KR20240085798A (ko) | 2020-04-03 | 2024-06-17 | 비스테라, 인크. | 항체 분자-약물 접합체 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JPH04211393A (ja) | 1990-02-08 | 1992-08-03 | Sumitomo Pharmaceut Co Ltd | ヒトモノクローナル抗体及びそれを有効成分とする緑膿菌感染症治療剤 |
| EP1319025A2 (en) | 2000-09-07 | 2003-06-18 | John R. Schreiber | Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AU2002351208A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
-
2001
- 2001-09-07 EP EP01968629A patent/EP1319025A2/en not_active Withdrawn
- 2001-09-07 US US10/380,092 patent/US7972845B2/en not_active Expired - Fee Related
- 2001-09-07 WO PCT/US2001/028019 patent/WO2002020619A2/en not_active Ceased
- 2001-09-07 AU AU8886601A patent/AU8886601A/xx not_active Withdrawn
- 2001-09-07 CA CA002422204A patent/CA2422204A1/en not_active Abandoned
- 2001-09-07 JP JP2002525238A patent/JP2004514423A/ja active Pending
-
2011
- 2011-05-27 US US13/118,074 patent/US8986990B2/en not_active Expired - Fee Related
-
2015
- 2015-03-03 US US14/636,753 patent/US9089557B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7078492B2 (en) | Human antipneumococcal antibodies from non-human animals | |
| US9089557B2 (en) | Human antibodies against Pseudomonas aeruginosa LPS derived from transgenic xenomouse | |
| JP2004514423A5 (cg-RX-API-DMAC7.html) | ||
| KR20250061718A (ko) | 항-인플루엔자 b 바이러스 항체, 인플루엔자 b 바이러스의 검출용 시약 및 키트 | |
| CN105968200A (zh) | 抗人pd-l1人源化单克隆抗体及其应用 | |
| EP1539811A2 (en) | Production of bispecific molecules using polyethylene glycol linkers | |
| CN1589903A (zh) | 用淀粉样蛋白抗体除去淀粉样蛋白的方法 | |
| KR950701386A (ko) | 레스피라토리 신시티알 바이러스 감염증의 치료 및 예방용 항체(Antibodies For Treatment And Prevention Of Resipiratory Syncytial Virus infection) | |
| US20240417446A1 (en) | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein | |
| US20250304681A1 (en) | Anti-rage antibody, extracellular vesicle, and preparation method and use thereof | |
| JPS60155133A (ja) | アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン | |
| US20230391852A1 (en) | Single domain antibodies targeting sars coronavirus spike protein and uses thereof | |
| TW202225188A (zh) | 與ｃｄ３結合的多肽構建體 | |
| WO2024238346A1 (en) | Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof | |
| US20240218055A1 (en) | Lassa virus-specific nanobodies and methods of their use | |
| Nguyen et al. | Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries | |
| Landon et al. | Therapeutic antibodies | |
| US20240270851A1 (en) | Cross species single domain antibodies targeting pd-l1 for treating solid tumors | |
| CN113461817A (zh) | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 | |
| CN120500500A (zh) | 一种抗gpr87的抗体及其制备方法和应用 | |
| AU2007216785B2 (en) | Human Antibodies Against Pseudomonas Aeruginosa LPS Derived from Transgenic Xenomouse | |
| WO2025171238A1 (en) | Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof | |
| AU2016202118A1 (en) | Carrier immunoglobulins and uses thereof | |
| AU2001288866B2 (en) | Human antibodies against pseudomonas aeruginosa LPS derived from transgenic xenomouse | |
| CN120590524A (zh) | 具有广谱性中和牛病毒性腹泻病毒的单克隆抗体及其应用 |